NCT00871663View on ClinicalTrials.gov

Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)

PHASE1CompletedINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Solid TumorsLymphoma, Non-HodgkinMultiple MyelomaLeukemia, Lymphocytic, Chronic. B-Cell
Interventions
DRUG

SCH 727965

Dose escalation of SCH 727965 IV administered in 28-day cycles, on Days 1, 8, and 15 of each 28-day cycle.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00871663 - Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6) | Biotech Hunter | Biotech Hunter